USPTO 2015–2025 USPTO PatentsView US Corporation

Cascade Biosystems, Inc.

USPTO PatentsView assignee record - 16 granted patents across 1 technology areas, recorded in grant years 2015–2022. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C12Q (Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Micr).

RSS updates for this company

The verdict

According to USPTO PatentsView, Cascade ranks #17,534 of 49,997 tracked US assignees by granted-patent volume, with 16 patents across 1 technology areas.

#17,534
of 49,997 US assignees by volume
23rd percentile
by Innovation Score (27.2/100)
19.5
avg claims per patent
-40%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R17534 · US Corporation #17,534 · 16 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · VEL-DOWN · BOOK-FULL

  • GRANTS-MICRO 16 grants
  • MID-PACK #17,534/49,997
  • PHOTO-FINISH Calderco Holdings…
  • CPC-NARROW C12Q · 1 areas
  • INNOV-THIN 27.2/100
  • CLAIMS-RICH 19.5 claims/avg
  • TYPE-USCORP US Corporation
  • VEL-DOWN -40% vel
  • BOOK-FULL 10/10 fields

Nearest grant-volume peer: Calderco Holdings Group, LLC (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Cascade’s 27.2 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Innovation-score neighbourhood around Cascade

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows Cascade's Innovation Score is 27.2/100 (23rd percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

Does more volume mean deeper claims for Cascade?

Each dot is one of Cascade’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Cascade’s own 19.5 claims/patent is ABOVE the 10.9 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Cascade vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView. 2×2 strategic matrix plotting 9 entities by Granted patents (volume) (X) and Avg claims / patent (Y), with a crosshair dividing the plot into four quadrants. Volume + depthSelective & thoroughVolume over depthLean filer 15.915.91616.1 0510152025 Granted patents (volume) Avg claims / patent Curaden AG - 16, 1CuradenCalderco Holdings Group, LLC - 16, 10.94Calderco Holdings…Calphalon Corporation - 16, 7.44CalphalonCarbyne Ltd. - 16, 19CarbyneCelator Pharmaceuticals, Inc. - 16, 14.56Celator Pharmaceu…Centor Design Pty Ltd. - 16, 8.94Centor Design PtyCentric Software, Inc. - 16, 20.12Centric SoftwareCentricity Vision, Inc. - 16, 18.25Centricity VisionCascade Biosystems, Inc. - 16, 19.5Cascade Biosystems
Cascade vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Cascade's grants concentrate

Cascade Biosystems, Inc. is a focused PatentsView assignee: 1 CPC subclasses with 100% of grants classified under C12Q (Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Micr). Peak complete grant year is 2015 (3 grants) versus a trough of 1 in 2018. By volume, Cascade sits between Curaden AG and Centricity Vision, Inc..

Cascade's three-year grant acceleration

Cascade Biosystems, Inc. shows 2 grants in 2022–2024 against only 6 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Who files at Cascade's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Cascade holds 16 patents at rank #17,561, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Cascade

By rank, the assignees closest to #17,561 in granted patent volume.

Leaders in C12Q (Measuring OR Testing Processes Involving Enzymes)

Other assignees with the most granted patents in Cascade's primary technology class.

Cascade's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

27 23rd percentile higher than 23% of 49,997 US assignees

This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

0.511.522.533.5 20152016201720182019202020212022 2
USPTO utility patent grants by year · 2015–2022

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table
Cascade Biosystems, Inc. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2015 3 18.8%
2016 2 12.5%
2017 2 12.5%
2018 1 6.3%
2019 2 12.5%
2020 1 6.3%
2021 3 18.8%
2022 2 12.5%

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

What to do with this data

Cascade Biosystems, Inc.'s patent record in context - here's where to go next.

  • Cascade Biosystems, Inc.'s lead technology class is C12Q (Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Micr), 100% of its portfolio - see every assignee active in that class. Explore C12Q
  • Ranked #17,534 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
  • Compare Cascade Biosystems, Inc. against Curaden AG, an assignee filing at a similar volume. Compare portfolios
  • Innovation Score of 27.2/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.